Author

Kathryn Shea

Observed name: K Shea

Institution: Eutropics Pharmaceuticals (United States)

Observed institution: Eutropics Pharmaceuticals (United States)

ORCID: 0000-0001-9663-745X

Observed ORCID: 0000-0001-9663-745X

OpenAlex ID: A5010705346

A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

2019 · Mark A. Schroeder, Mark A. Fiala, et al. · Clinical Cancer Research · 20

A224 Lenalidomide, Bortezomib, and Dexamethasone Has Notable Activity in High-Risk First-Line Myeloma

2009 · PG Richardson, S Lonial, et al. · Clinical Lymphoma & Myeloma · 4

Works count: 2

Citation count: 24

H-index: 2

I10-index: 1